论文部分内容阅读
目的制备阿昔洛韦纳米乳剂,探讨其在大鼠体内的药代动力学。方法对大鼠尾静脉注射后不同时间点眼眶采血,用HPLC法测定阿昔洛韦血药浓度,3p87软件拟合药动学参数。结果阿昔洛韦在大鼠体内呈二室模型,t1/2α为20.74min,t1/2β为380.87min,清除率(CL)为0.0018。结论将阿昔洛韦制成纳米乳剂可提高其相对生物利用度,从而增强其抗病毒作用。
Objective To prepare acyclovir nanoemulsion and investigate its pharmacokinetics in rats. Methods The orbital blood samples were collected at different time points after tail vein injection in rats. The plasma concentration of acyclovir was determined by HPLC and the pharmacokinetic parameters were fitted by 3p87 software. Results Acyclovir showed a two compartment model in rat. The t1 / 2α was 20.74min, the t1 / 2β was 380.87min, the clearance rate (CL) was 0.0018. Conclusion Acyclovir nanoemulsion can improve its relative bioavailability and enhance its antiviral effect.